Molecular mechanisms of IFN-γ to up-regulate MHC class i antigen processing and presentation

International Reviews of Immunology

Volumn 28, Issue 3-4, 2009, Pages 239-260

  Zhou, Fang ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antigen processing and presentation; IFN ; JAK STAT signal transduction pathway; MHC class I

Indexed keywords

ABC TRANSPORTER; AMINOPEPTIDASE; DNA; ENDOPLASMIC RETICULUM ASSOCIATED AMINOPEPTIDASE 1; ENDOPLASMIC RETICULUM ASSOCIATED AMINOPEPTIDASE 2; FURIN; GAMMA INTERFERON; HLA A3 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 1; JANUS KINASE 1; JANUS KINASE 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METALLOPROTEINASE; NEF PROTEIN; PEPTIDASE; PROTEASOME; PROTEASOME ACTIVATOR 28; PROTEASOME MATURATION PROTEIN; PROTEIN; STAT1 PROTEIN; TAPASIN; TRANSPORTER ASSOCIATED ANTIGEN PROCESSING; TRI PEPTIDYL PEPTIDASE II; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BIOGENESIS; CYTOTOXIC T LYMPHOCYTE; DNA BINDING; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTIGEN PRESENTATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 71049192398     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.1080/08830180902978120     Document Type: Review

References (163)

1. U. Boehm, T. Klamp, M. Groot, and J.C. Howard. Cellular responses to interferongamma. Annu Rev Immunol 15: 749-795, 1997.
2. F.M. Rosa and M. Fellous. Regulation of HLA-DR gene by IFN-gamma. Transcriptional and post-transcriptional control. J Immunol 140: 1660-1664, 1988.
3. B.M. Foxwell, K. Barrett, and M. Feldmann. Cytokine receptors: Structure and signal transduction. Clin Exp Immunol 90: 161-169, 1992.
4. B.E. Szente, J.M. Soos, and H.W. Johnson. The C-terminus of IFN gamma is sufficient for intracellular function. Biochem Biophys Res Commun 203: 1645-1654, 1994.
5. J. Briscoe, D. Guschin, N.C. Rogers, D. Watling, M. Muller, F. Horn, P. Heinrich, G.R. Stark, and I.M. Kerr. JAKs, STATs and signal transduction in response to the interferons and other cytokines. Philos Trans R Soc Lond B Biol Sci 351: 167-171, 1996.
6. F. Kohlhuber, N.C. Rogers, D. Watling, J. Feng, D. Guschin, J. Briscoe, B.A. Witthuhn, S.V. Kotenko, S. Pestka, G.R. Stark, J.N. Ihle, and I.M. Kerr. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol 17: 695-706, 1997.
7. A.J. Wu, Z.J. Chen, E.C. Kan, and B.J. Baum. Interferon-gamma-induced JAK2 and STAT1 signalling in a human salivary gland cell line. J Cell Physiol 173: 110-114, 1997.
8. I.M. Svane, A.M. Engel, M. Nielsen, and O. Werdelin. Interferon-gamma- induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthreneinduced sarcomas. Scand J Immunol 46: 379-387, 1997.
9. I.M. Kerr, A.P. Costa-Pereira, B.F. Lillemeier, and B. Strobl. Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett 546: 1-5, 2003.
10. D.M. Miller, B.M. Rahill, J.M. Boss, M.D. Lairmore, J.E. Durbin, J.W. Waldman, and D.D. Sedmak. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med 187: 675-683, 1998.
11. E. Jouanguy, F. Altare, S. Lamhamedi-Cherradi, and J.L. Casanova. Infections in IFNGR-1-deficient children. J Interferon Cytokine Res 17: 583-587, 1997.
12. S. Li, S. Labrecque, M.C. Gauzzi, A.R. Cuddihy, A.H. Wong, S. Pellegrini, G.J. Matlashewski, and A.E. Koromilas. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 18: 5727-5737, 1999.
13. H. Skrenta, Y. Yang, S. Pestka, and C.G. Fathman. Ligand-independent downregulation of IFN-gamma receptor 1 following TCR engagement. J Immunol 164: 3506-3511, 2000.
14. E. Jouanguy, S. Dupuis, A. Pallier, R. Doffinger, M.C. Fondaneche, C. Fieschi, S. Lamhamedi, Cherradi, F. Altare, J.F. Emile, P. Lutz, P. Bordigoni, H. Cokugras, N. Akcakaya, J. Landman-Parker, J. Donnadieu, Y. Camcioglu, and J.L. Casanova. In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma. J Clin Invest 105: 1429-1436, 2000.
15. Y.P. Wei, M. Kita, K. Shinmura, X.Q. Yan, R. Fukuyama, S. Fushiki, and J. Imanishi. Expression of IFN-gamma in cerebrovascular endothelial cells from aged mice. J Interferon Cytokine Res 20: 403-409, 2000.
16. Y. Takei, T.N. Sims, J. Urmson, and P.F. Halloran. Central role for interferongamma receptor in the regulation of renal MHC expression. J AmSocNephrol 11: 250-261, 2000.
17. M. Delgado and D. Ganea. Inhibition of IFN-gamma-induced janus kinase-1- STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol 165: 3051-3057, 2000.
18. L.M. Allende, A. Lopez-Goyanes, E. Paz-Artal, A. Corell, M.A. Garcia-Perez, P. Varela, A. Scarpellini, S. Negreira, E. Palenque, and A. Arnaiz-Villena. A point mutation in a domain of gamma interferon receptor 1 provokes severe immunodeficiency. Clin Diagn Lab Immunol 8: 133-137, 2001. (Pubitemid 32061696)
19. O. Koch, A. Awomoyi, S. Usen, M. Jallow, A. Richardson, J. Hull, M. Pinder, M. Newport, and D. Kwiatkowski. IFNGR1 gene promoter polymorphisms and susceptibility to cerebral malaria. J Infect Dis 185: 1684-1687, 2002.
20. D.A. Fraser, B.G. Loos, U. Boman, A.J. van Winkelhoff, U. van der Velden, K. Schenck, and Z. Dembic. Polymorphisms in an interferon-gamma receptor-1 gene marker and susceptibility to periodontitis. Acta Odontol Scand 61: 297-302, 2003.
21. K. Tiroch, N. von Beckerath, W. Koch, J. Lengdobler, A. Joost, A. Schomig, and A. Kastrati. Interferon-gamma and interferon-gamma receptor 1 and 2 gene polymorphisms and restenosis following coronary stenting. Atherosclerosis 182: 145-151, 2005.
22. C. Hindinger, J.M. Gonzalez, C.C. Bergmann, B. Fuss, D.R. Hinton, R.D. Atkinson, W.B. Macklin, and S.A. Stohlman. Astrocyte expression of a dominant-negative interferon-gamma receptor. J Neurosci Res 82: 20-31, 2005.
23. K. Fruh and Y. Yang. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 11: 76-81, 1999.
24. M.C. Rouyez, M. Lestingi, M. Charon, S. Fichelson, A. Buzyn, and I. Dusanter- Fourt. IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity. J Immunol 174: 3948-3958, 2005.
25. K. Mahboubi and J.S. Pober. Activation of signal transducer and activator of transcription 1 (STAT1) is not sufficient for the induction of STAT1-dependent genes in endothelial cells. Comparison of interferon-gamma and oncostatin M. J Biol Chem 277: 8012-8021, 2002.
26. L. Marques, M. Brucet, J. Lloberas, and A. Celada. STAT1 regulates lipopolysaccharide- and TNF-alpha-dependent expression of transporter associated with antigen processing 1 and low molecular mass polypeptide 2 genes in macrophages by distinct mechanisms. J Immunol 173: 1103-1110, 2004.
27. K. Mori, S. Stone, L. Khaodhiar, L.E. Braverman, and W.J. DeVito. Induction of transcription factor interferon regulatory factor-1 by interferon-gamma (IFN gamma) and tumor necrosis factor-alpha (TNF alpha) in FRTL-5 cells. J Cell Biochem 74: 211-219, 1999.
28. T. Rein, M. Muller, and H. Zorbas. In vivo footprinting of the IRF-1 promoter: Inducible occupation of a GAS element next to a persistent structural alteration of the DNA. Nucleic Acids Res 22: 3033-3037, 1994.
29. M. Saura, C. Zaragoza, C. Bao, A. McMillan, and C.J. Lowenstein. Interaction of interferon regulatory factor-1 and nuclear factor kappaB during activation of inducible nitric oxide synthase transcription. J Mol Biol 289: 459-471, 1999.
30. K. Storm van's Gravesande, M.D. Layne, Q. Ye, L. Le, R.M. Baron, M.A. Perrella, L. Santambrogio, E.S. Silverman, and R.J. Riese. IFN regulatory factor-1 regulates IFN-gamma-dependent cathepsin S expression. J Immunol 168: 4488-4494, 2002.
31. M. Giroux, M. Schmidt, and A. Descoteaux. IFN-gamma-induced MHC class II expression: Transactivation of class II transactivator promoter IV by IFN regulatory factor-1 is regulated by protein kinase C-alpha. J Immunol 171: 4187-4194, 2003.
32. Y. Guo, T. Yang, X. Liu, S. Lu, J. Wen, J.E. Durbin, Y. Liu, and P. Zheng. Cis elements for transporter associated with antigen-processing-2 transcription: Two new promoters and an essential role of the IFN response factor binding element in IFN-gamma-mediated activation of the transcription initiator. Int Immunol 14: 189-200, 2002.
33. A.H. Lee, J.H. Hong, and Y.S. Seo. Tumour necrosis factor-alpha and interferongamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors. Biochem J 350: 131-138, 2000.
34. Q.P. Liu, K. Fruit, J. Ward, and P.H. Correll. Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase. J Immunol 163: 6606-6613, 1999.
35. F. Ossendorp, N. Fu, M. Camps, F. Granucci, S.J. Gobin, P.J. van den Elsen, D. Schuurhuis, G.J. Adema, G.B. Lipford, T. Chiba, A. Sijts, P.M.Kloetzel, P. Ricciardi- Castagnoli, and C.J. Melief. Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. J Immunol 174: 7815-11722, 2005.
36. P.D. Drew, G. Franzoso, K.G. Becker, V. Bours, L.M. Carlson, U. Siebenlist, and K. Ozato. NF kappa B and interferon regulatory factor 1 physically interact and synergistically induce major histocompatibility class I gene expression. J Interferon Cytokine Res 15: 1037-1045, 1995.
37. A. Lehtonen, S. Matikainen, and I. Julkunen. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J Immunol 159: 794-803, 1997.
38. K.R. Morris, R.D. Lutz, H.S. Choi, T. Kamitani, K. Chmura, and E.D. Chan. Role of the NF-kappaB signaling pathway and kappaB cis-regulatory elements on the IRF-1 and iNOS promoter regions in mycobacterial lipoarabinomannan induction of nitric oxide. Infect Immun 71: 1442-1452, 2003.
39. S.R. Paludan, S. Ellermann-Eriksen, and S.C. Mogensen. NF-kappaB activation is responsible for the synergistic effect of herpes simplex virus type 2 infection on interferon-gamma-induced nitric oxide production in macrophages. J Gen Virol 79: 2785-2793, 1998.
40. S.R. Paludan, L.Malmgaard, S. Ellermann-Eriksen, L. Bosca, and S.C. Mogensen. Interferon (IFN)-gamma and Herpes simplex virus/tumor necrosis factor-alpha synergistically induce nitric oxide synthase 2 in macrophages through cooperative action of nuclear factor-kappa B and IFN regulatory factor-1. Eur Cytokine Netw 12: 297-308, 2001.
41. S.Y. Chon, H.H. Hassanain, and S.L. Gupta. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma- inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem271: 17247-17252, 1996.
42. C. Haan, S. Kreis, C. Margue, and I. Behrmann. Jaks and cytokine receptors-an intimate relationship. Biochem Pharmacol 72: 1538-1546, 2006.
43. J.S. Rawlings, K.M. Rosler, and D.A. Harrison. The JAK/STAT signaling pathway. J Cell Sci 117: 1281-1283, 2004.
44. P.J. Murray. The JAK-STAT signaling pathway: Input and output integration. J Immunol 178: 2623-2629, 2007.
45. K. Shuai and B. Liu. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3: 900-911, 2003.
46. S. Ilangumaran and R. Rottapel. Regulation of cytokine receptor signaling by SOCS1. Immunol Rev 192: 196-211, 2003.
47. L. Larsen and C. Ropke. Suppressors of cytokine signalling: SOCS. Apmis 110: 833-844, 2002.
48. B.Q. Vuong, T.L. Arenzana, B.M. Showalter, J. Losman, X.P. Chen, J. Mostecki, A.S. Banks, A. Limnander, N. Fernandez, and P.B. Rothman. SOCS-1 localizes to the microtubule organizing complex-associated 20S proteasome. Mol Cell Biol 24: 9092-9101, 2004.
49. D. Hebenstreit, J. Horejs-Hoeck, and A. Duschl. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect 18: 243-249, 2005.
50. E. Ingley, and S.P. Klinken. Cross-regulation of JAK and Src kinases. Growth Factors 24: 89-95, 2006.
51. M.E. Baldeon, D.J. Neece, D. Nandi, J.J. Monaco, and H.R. Gaskins. Interferongamma independently activates the MHC class I antigen processing pathway and diminishes glucose responsiveness in pancreatic beta-cell lines. Diabetes 46: 770-778, 1997.
52. H. Fujimaki, N. Hikawa, M. Nagoya, T. Nagata, and M. Minami. IFN-gamma induces expression of MHC class I molecules in adult mouse dorsal root ganglion neurones. Neuroreport 7: 2951-2955, 1996. (Pubitemid 26426367)
53. G.R. Leggatt, L.A. Dunn, R.L. De Kluyver, T. Stewart, and I.H. Frazer. Interferongamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Immunol Cell Biol 80: 415-424, 2002.
54. S.J. Gobin, M. van Zutphen, A.M. Woltman, and P.J. van den Elsen. Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J Immunol 163: 1428-1434, 1999.
55. S.J. Gobin, A. Peijnenburg, V. Keijsers, and P.J. van den Elsen. alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: The ISREmediated route and a novel pathway involving CIITA. Immunity 6: 601-611, 1997.
56. R. De Caterina, T. Bourcier, U. Laufs, V. La Fata, G. Lazzerini, A.S. Neish, P. Libby, and J.K. Liao. Induction of endothelial-leukocyte interaction by interferon-gamma requires coactivation of nuclear factor-kappaB. Arterioscler Thromb Vasc Biol 21: 227-232, 2001.
57. K. Beppu, T. Morisaki, H. Matsunaga, A. Uchiyama, E. Ihara, K. Hirano, H. Kanaide, M. Tanaka, and M. Katano. Inhibition of interferon-gamma-activated nuclear factor-kappa B by cyclosporin A: A possible mechanism for synergistic induction of apoptosis by interferon-gamma and cyclosporin A in gastric carcinoma cells. Biochem Biophys Res Commun 305: 797-805, 2003.
58. P.D. Drew, M. Lonergan, M.E. Goldstein, L.A. Lampson, K. Ozato, and D.E. McFarlin. Regulation of MHC class I and beta 2-microglobulin gene expression in human neuronal cells. Factor binding to conserved cis-acting regulatory sequences correlates with expression of the genes. J Immunol 150: 3300-3310, 1993.
59. S.J. Gobin and P.J. van den Elsen. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol 61: 1102-1107, 2000.
60. A.R. Bluyssen, J.E. Durbin, and D.E. Levy. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev 7: 11-17, 1996.
61. S. Majumder, L.Z. Zhou, P. Chaturvedi, G. Babcock, S. Aras, and R.M. Ransohoff. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. J Immunol 161: 4736-4744, 1998.
62. T. Kimura, Y. Kadokawa, H. Harada, M. Matsumoto, M. Sato, Y. Kashiwazaki, M. Tarutani, R.S. Tan, T. Takasugi, T. Matsuyama, T.W. Mak, S. Noguchi, and T. Taniguchi. Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1: 115-124, 1996.
63. S. Kadereit, J. Galabru, N. Robert, E.F. Meurs, and A.G. Hovanessian. Characterization of an interferon-induced 48-kD protein immunologically related to the double-stranded RNA-activated protein kinase PKR. J Interferon Res 14: 251-257, 1994.
64. X. Weihua, V. Kolla, and D.V. Kalvakolanu. Interferon gamma-induced transcription of themurine ISGF3gamma (p48) gene is mediated by novel factors. Proc Natl Acad Sci U S A 94: 103-108, 1997.
65. H.A. Bluyssen and D.E. Levy. Stat2 is a transcriptional activator that requires sequence-specific contacts provided by stat1 and p48 for stable interaction with DNA. J Biol Chem272: 4600-4605, 1997.
66. L.H. Wong, I. Hatzinisiriou, R.J. Devenish, and S.J. Ralph. IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs. J Immunol 160: 5475-5484, 1998.
67. M. Matsumoto, N. Tanaka, H. Harada, T. Kimura, T. Yokochi, M. Kitagawa, C. Schindler, and T. Taniguchi. Activation of the transcription factor ISGF3 by interferon-gamma. Biol Chem 380: 699-703, 1999.
68. W. Xiao, L. Wang, X. Yang, T. Chen, D. Hodge, P.F. Johnson, and W. Farrar. CCAAT/enhancer-binding protein beta mediates interferon-gamma-induced p48 (ISGF3-gamma) gene transcription in human monocytic cells. J Biol Chem 276: 23275-23281, 2001.
69. S.F. Matin, R.R. Rackley, P.C. Sadhukhan, M.S. Kim, A.C. Novick, and S.K. Bandyopadhyay. Impaired alpha-interferon signaling in transitional cell carcinoma: Lack of p48 expression in 5637 cells. Cancer Res 61: 2261-2266, 2001.
70. W. Ma, P.J. Lehner, P. Cresswell, J.S. Pober, and D.R. Johnson. Interferon-gamma rapidly increases peptide transporter (TAP) subunit expression and peptide transport capacity in endothelial cells. J Biol Chem272: 16585-16590, 1997.
71. B. Seliger, S. Hammers, A. Hohne, R. Zeidler, A. Knuth, C.D. Gerharz, and C. Huber. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res 3: 573-578, 1997.
72. R.J. Tatake, S. Ferrone, and R.A. Zeff. The role of beta-2 microglobulin in temperature-sensitive and interferon-gamma-induced exocytosis of HLA class I molecules. Transplantation 54: 395-403, 1992.
73. U. Zugel, B. Schoel, and S.H. Kaufmann. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone. J Immunol 153: 4070-4080, 1994.
74. J.M. Romero, P. Jimenez, T. Cabrera, J.M. Cozar, S. Pedrinaci, M. Tallada, F. Garrido, and F. Ruiz-Cabello. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 113: 605-610, 2005.
75. R. Schiffer, J. Baron, G. Dagtekin,W. Jahnen-Dechent, and G. Zwadlo-Klarwasser. Differential regulation of the expression of transporters associated with antigen processing, TAP1 and TAP2, by cytokines and lipopolysaccharide in primary human macrophages. Inflamm Res 51: 403-408, 2002.
76. N. Garbi, P. Tan, A.D. Diehl, B.J. Chambers, H.G. Ljunggren, F. Momburg, and G.J. Hammerling. Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol 1: 234-238, 2000.
77. P.J. Chefalo, A.G. Grandea, 3rd, L. Van Kaer, and C.V. Harding. Tapasin-/- and TAP1-/- macrophages are deficient in vacuolar alternate class I MHC (MHC-I) processing due to decreased MHC-I stability at phagolysosomal pH. J Immunol 170: 5825-5833, 2003.
78. A.G. Grandea, 3rd and L. Van Kaer. Tapasin: An ER chaperone that controls MHC class I assembly with peptide. Trends Immunol 22: 194-199, 2001.
79. A.G. Grandea, 3rd, T.N. Golovina, S.E. Hamilton, V. Sriram, T. Spies, R.R. Brutkiewicz, J.T. Harty, L.C. Eisenlohr, and L. Van Kaer. Impaired assembly yet normal trafficking of MHC class I molecules in Tapasin mutant mice. Immunity 13: 213-222, 2000.
80. M. Howarth, A. Williams, A.B. Tolstrup, and T. Elliott. Tapasin enhances MHC class I peptide presentation according to peptide half-life. Proc Natl Acad Sci U S A 101: 11737-11742, 2004.
81. S.V. Fromm, S. Duady-Ben Yaakov, C. Schechter, and R. Ehrlich. Assembly and cell surface expression of TAP-independent, chloroquine-sensitive and interferongamma- inducible class I MHC complexes in transformed fibroblast cell lines are regulated by tapasin. Cell Immunol 215: 207-218, 2002.
82. B. Seliger, K. Schreiber, K. Delp, M. Meissner, S. Hammers, T. Reichert, K. Pawlischko, R. Tampe, and C. Huber. Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens 57: 39-45, 2001.
83. R. Demine and P.Walden. Testing the role of gp96 as peptide chaperone in antigen processing. J Biol Chem280: 17573-17578, 2005.
84. A. Heikema, E. Agsteribbe, J. Wilschut, and A. Huckriede. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol Lett 57: 69-74, 1997.
85. A. Menoret, P. Peng, and P.K. Srivastava. Association of peptides with heat shock protein gp96 occurs in vivo and not after cell lysis. Biochem Biophys Res Commun 262: 813-818, 1999.
86. J. Robert, T. Ramanayake, G.D. Maniero, H. Morales, and A.S. Chida. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J Immunol 180: 3176-3182, 2008.
87. B. Dahlmann. Proteasomes. Essays Biochem 41: 31-48, 2005.
88. A.L. Goldberg, M. Gaczynska, E. Grant, M. Michalek, and K.L. Rock. Functions of the proteasome in antigen presentation. Cold Spring Harb Symp Quant Biol 60: 479-490, 1995.
89. S. Heink, D. Ludwig, P.M. Kloetzel, and E. Kruger. IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci U S A 102: 9241-9246, 2005.
90. J.J. Monaco. and D. Nandi. The genetics of proteasomes and antigen processing. Annu Rev Genet 29: 729-754, 1995.
91. K. Tanaka. Role of proteasomes modified by interferon-gamma in antigen processing. J Leukoc Biol 56: 571-575, 1994.
92. S. Bose, F.L. Stratford, K.I. Broadfoot, G.G. Mason, and A.J. Rivett. Phosphorylation of 20S proteasome alpha subunit C8 (alpha7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by gamma-interferon. Biochem J 378: 177-184, 2004.
93. S. Bose, P. Brooks, G.G. Mason, and A.J. Rivett. gamma-Interferon decreases the level of 26 S proteasomes and changes the pattern of phosphorylation. Biochem J 353: 291-297, 2001.
94. V. Ortiz-Navarrete, A. Seelig, M. Gernold, S. Frentzel, P.M. Kloetzel, and G.J. Hammerling. Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature 353: 662-664, 1991.
95. B. Boes, H. Hengel, T. Ruppert, G.Multhaup, U.H. Koszinowski, and P.M. Kloetzel. Interferon gamma stimulationmodulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med 179: 901-909, 1994.
96. M. Groettrup, R. Kraft, S. Kostka, S. Standera, R. Stohwasser, and P.M. Kloetzel. A third interferon-gamma-induced subunit exchange in the 20S proteasome. Eur J Immunol 26: 863-869, 1996.
97. D. Nandi, E. Woodward, D.B. Ginsburg, and J.J. Monaco. Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor beta subunits. Embo J 16: 5363-5375, 1997.
98. M. Groettrup, S. Khan, K. Schwarz, and G. Schmidtke. Interferon-gamma inducible exchanges of 20S proteasome active site subunits: Why? Biochimie 83: 367-372, 2001.
99. M. Unno, T. Mizushima, Y. Morimoto, Y. Tomisugi, K. Tanaka, N. Yasuoka, and T. Tsukihara. The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure (Camb) 10: 609-618, 2002.
100. M. Aki, et al. Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem (Tokyo) 115: 257-269, 1994.
101. M. Groettrup, S. Standera, R. Stohwasser, and P.M. Kloetzel. The subunits MECL- 1 and LMP2 aremutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci U S A 94: 8970-8975, 1997.
102. P. Cascio and A.L. Goldberg. Preparation of hybrid (19S-20S-PA28) proteasome complexes and analysis of peptides generated during protein degradation. Methods Enzymol 398: 336-352, 2005.
103. A.L. Goldberg, P. Cascio, T. Saric, and K.L. Rock. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39: 147-164, 2002.
104. A.J. Rivett, S. Bose, P. Brooks, and K.I. Broadfoot. Regulation of proteasome complexes by gamma-interferon and phosphorylation. Biochimie 83: 363-366, 2001.
105. P. Brooks, G. Fuertes, R.Z. Murray, S. Bose, E. Knecht, M.C. Rechsteiner, K.B. Hendil, K. Tanaka, J. Dyson, and J. Rivett. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J 346: 155-161, 2000.
106. E. Berezutskaya and S. Bagchi. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J Biol Chem 272: 30135-30140, 1997.
107. A. Eichten, M. Westfall, J.A. Pietenpol, and K. Munger. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology 295: 74-85, 2002.
108. M. Smahel, P. Sima, V. Ludvikova, I. Marinov, D. Pokorna, and V. Vonka. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 21: 1125-1136, 2003.
109. W.H. Kao, S.L. Beaudenon, A.L. Talis, J.M. Huibregtse, and P.M. Howley. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitinprotein ligase. J Virol 74: 6408-6417, 2000.
110. Q. Gao, A. Kumar, L. Singh, J.M. Huibregtse, S. Beaudenon, S. Srinivasan, D.E. Wazer, H. Band, and V. Band. Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res 62: 3315-3321, 2002.
111. M. Lagrange, S. Charbonnier, G. Orfanoudakis, P. Robinson, K. Zanier,M.Masson, Y. Lutz, G. Trave, E. Weiss, and F. Deryckere. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6. J Gen Virol 86: 1001-1007, 2005.
112. M.C. Thomas and C.M. Chiang. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 17: 251-264, 2005.
113. M. Groettrup, T. Ruppert, L. Kuehn, M. Seeger, S. Standera, U. Koszinowski, and P.M. Kloetzel. The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J Biol Chem270: 23808-23815, 1995.
114. D. Nandi, H. Jiang, and J.J. Monaco. Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol 156: 2361-2364, 1996.
115. K. Akiyama, S. Kagawa, T. Tamura, N. Shimbara, M. Takashina, P. Kristensen, K.B. Hendil, K. Tanaka, and A. Ichihara. Replacement of proteasome subunits X and Y by LMP7 and LMP2 induced by interferon-gamma for acquirement of the functional diversity responsible for antigen processing. FEBS Lett 343: 85-88, 1994.
116. A.J. Sijts, T. Ruppert, B. Rehermann, M. Schmidt, U. Koszinowski, and P.M. Kloetzel. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med 191: 503-514, 2000.
117. W.O. Bocher, B. Dekel, W. Schwerin, M. Geissler, S. Hoffmann, A. Rohwer, F. Arditti, A. Cooper, H. Bernhard, A. Berrebi, S. Rose-John, Y. Shaul, P.R. Galle, H.F. Lohr, and Y. Reisner. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur J Immunol 31: 2071-2079, 2001.
118. W. Xu, Y. Chu, R. Zhang, H. Xu, Y. Wang, and S. Xiong. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine. Virology 334: 255-263, 2005.
119. E. Witt, D. Zantopf, M. Schmidt, R. Kraft, P.M. Kloetzel, and E. Kruger. Characterisation of the newly identified human Ump1 homologue POMP and analysis of LMP7(beta 5i) incorporation into 20 S proteasomes. J Mol Biol 301: 1-9, 2000.
120. I.A. York, A.L. Goldberg, X.Y. Mo, and K.L. Rock. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev 172: 49-66, 1999.
121. S.L. McCutchen-Maloney, K. Matsuda, N. Shimbara, D.D. Binns, K. Tanaka, C.A. Slaughter, and G.N. DeMartino. cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome. J Biol Chem 275: 18557-18565, 2000.
122. D.M. Zaiss, S. Standera, H. Holzhutter, P. Kloetzel, and A.J. Sijts. The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes. FEBS Lett 457: 333-338, 1999.
123. N. Tanahashi, H. Kawahara, Y. Murakami, and K. Tanaka. The proteasomedependent proteolytic system.Mol Biol Rep 26: 3-9, 1999.
124. D.M. Zaiss, S. Standera, P.M. Kloetzel, and A.J. Sijts. PI31 is a modulator of proteasome formation and antigen processing. Proc Natl Acad Sci U S A 99: 14344-14349, 2002.
125. G.A. Azar, R.P. Sekaly, and J. Thibodeau. A defective viral superantigen-presenting phenotype in HLA-DR transfectants is corrected by CIITA. J Immunol 174: 7548-7557, 2005.
126. N. Tanahashi, K. Yokota, J.Y. Ahn, C.H. Chung, T. Fujiwara, E. Takahashi, G.N. DeMartino, C.A. Slaughter, T. Toyonaga, K. Yamamura, N. Shimbara, and K. Tanaka. Molecular properties of the proteasome activator PA28 family proteins and gamma-interferon regulation. Genes Cells 2: 195-211, 1997.
127. J.Y. Ahn, N. Tanahashi, K. Akiyama, H. Hisamatsu, C. Noda, K. Tanaka, C.H. Chung, N. Shibmara, P.J. Willy, and J.D. Mott. Primary structures of two homologous subunits of PA28, a gamma-interferon-inducible protein activator of the 20S proteasome. FEBS Lett 366: 37-42, 1995.
128. M. Groettrup, A. Soza, M. Eggers, L. Kuehn, T.P. Dick, H. Schild, H.G. Rammensee, U.H. Koszinowski, and P.M. Kloetzel. A role for the proteasome regulator PA28alpha in antigen presentation. Nature 381: 166-168, 1996.
129. K. Schwarz, M. Eggers, A. Soza, U.H. Koszinowski, P.M. Kloetzel, and M. Groettrup. The proteasome regulator PA28alpha/beta can enhance antigen presentation without affecting 20S proteasome subunit composition. Eur J Immunol 30: 3672-3679, 2000.
130. K.B. Hendil, S. Khan, and K. Tanaka. Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes. Biochem J 332: 749-754, 1998.
131. D.H. Kim, S.M. Lee, B.Y. Hong, Y.T. Kim, and T.J. Choi. Cloning and sequence analysis of cDNA for the proteasome activator PA28-beta subunit of flounder (Paralichthys olivaceus). Mol Immunol 40: 611-616, 2003.
132. D. McCusker,M.Wilson, and J. Trowsdale. Organization of the genes encoding the human proteasome activators PA28alpha and beta. Immunogenetics 49: 438-445, 1999.
133. A. Sijts, Y. Sun, K. Janek, S. Kral, A. Paschen, D. Schadendorf, and P.M. Kloetzel. The role of the proteasome activator PA28 in MHC class I antigen processing. Mol Immunol 39: 165-169, 2002.
134. M. Rechsteiner, C. Realini, and V. Ustrell. The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J 345: 1-15, 2000.
135. Y. Yao, L. Huang, A. Krutchinsky, M.L. Wong, K.G. Standing, A.L. Burlingame, and C.C. Wang. Structural and functional characterizations of the proteasomeactivating protein PA26 from Trypanosoma brucei.J Biol Chem274: 33921-33930, 1999.
136. T. van Hall, A. Sijts, M. Camps, R. Offringa, C. Melief, P.M. Kloetzel, and F. Ossendorp. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J Exp Med 192: 483-494, 2000.
137. A. Sijts, D. Zaiss, and P.M. Kloetzel. The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr Mol Med 1: 665-676, 2001.
138. S. Murata, H. Udono, N. Tanahashi, N. Hamada, K. Watanabe, K. Adachi, T. Yamano, K. Yui, N. Kobayashi, M. Kasahara, K. Tanaka, and T. Chiba. Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. EMBO J 20: 5898-5907, 2001.
139. Y. Sun, A.J. Sijts, M. Song, K. Janek, A.K. Nussbaum, S. Kral, M. Schirle, S. Stevanovic, A. Paschen, H. Schild, P.M. Kloetzel, and D. Schadendorf. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res 62: 2875-2882, 2002.
140. T. Yamano, S. Murata, N. Shimbara, N. Tanaka, T. Chiba, K. Tanaka, K. Yui, and H. Udono. Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing. J Exp Med 196: 185-196, 2002.
141. T. Yamano, H. Sugahara, S. Mizukami, S. Murata, T. Chiba, K. Tanaka, K. Yui, and H. Udono. Allele-selective effect of PA28 in MHC class I antigen processing. J Immunol 181: 1655-1664, 2008.
142. P.M. Kloetzel and F. Ossendorp. Proteasome and peptidase function in MHC-class- I-mediated antigen presentation. Curr Opin Immunol 16: 76-81, 2004.
143. G.E. Hammer, F. Gonzalez,M. Champsaur, D. Cado, andN. Shastri. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 7: 103-112, 2006.
144. T. Serwold, F. Gonzalez, J. Kim, R. Jacob, and N. Shastri. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419: 480-483, 2002.
145. T. Saric, S.C. Chang, A. Hattori, I.A. York, S. Markant, K.L. Rock, M. Tsujimoto, and A.L. Goldberg. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 3: 1169-1176, 2002.
146. R. Maile, K.A. Elsegood, T.C. Harding, J.B. Uney, C.E. Stewart, G. Banting, and C.M. Dayan. Effective formation of major histocompatibility complex class IIpeptide complexes from endogenous antigen by thyroid epithelial cells. Immunology 99: 367-374, 2000.
147. J. Lu, P.J. Wettstein, Y. Higashimoto, E. Appella, and E. Celis. TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol 166: 7063-7071, 2001.
148. P.W. O'Donnell, A. Haque, M.J. Klemsz, M.H. Kaplan, and J.S. Blum. Cutting edge: Induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells. Is STAT1-dependent but CIITA-independent. J Immunol 173: 731-735, 2004.
149. P. Brooks, R.Z. Murray, G.G. Mason, K.B. Hendil, and A.J. Rivett. Association of immunoproteasomes with the endoplasmic reticulum. Biochem J 352: 611-615, 2000.
150. S. Bulik, B. Peters, C. Ebeling, and H. Holzhutter. Cytosolic processing of proteasomal cleavage products can enhance the presentation efficiency of MHC-1 epitopes. Genome Inform 15: 24-34, 2004.
151. A.J. Book, P. Yang, M. Scalf, L.M. Smith, and R.D. Vierstra. Tripeptidyl peptidase II. An oligomeric protease complex from Arabidopsis. Plant Physiol 138: 1046-1057, 2005.
152. H. DeWinter,H. Breslin, T.Miskowski, R. Kavash, and M. Somers. Inhibitor-based validation of a homology model of the active-site of tripeptidyl peptidase II. J Mol Graph Model 23: 409-418, 2005.
153. G. Malandrinos, M. Louloudi, A.I. Koukkou, I. Sovago, C. Drainas, and N. Hadjiliadis. Zinc(II) and cadmium(II) metal complexes of thiamine pyrophosphate and 2-(alpha-hydroxyethyl)thiamine pyrophosphate:Models for activation of pyruvate decarboxylase. J Biol Inorg Chem 5: 218-226, 2000.
154. E. Reits, J. Neijssen, C. Herberts,W. Benckhuijsen, L. Janssen, J.W. Drijfhout, and J. Neefjes. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20: 495-506, 2004.
155. I.A. York, N. Bhutani, S. Zendzian, A.L. Goldberg, and K.L. Rock. Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J Immunol 177: 1434-1443, 2006.
156. T. Luft,M. Rizkalla, T.Y. Tai, Q. Chen, R.I. MacFarlan, I.D. Davis, E. Maraskovsky, and J. Cebon. Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: Intracellular loading and kinetics of presentation. J Immunol 167: 2529-2537, 2001.
157. O. Ayalon, E.A. Hughes, P. Cresswell, J. Lee, L. O'Donnell, R. Pardi, and J.R. Bender. Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis. Proc Natl Acad Sci U S A 95: 2435-2440, 1998.
158. K. Kuroda, K. Yamashina, N. Kitatani, A. Kagishima, T. Hamaoka, and Y. Hosaka. Characterization of defectiveness in endogenous antigen presentation of novel murine cells established from methylcholanthrene-induced fibrosarcomas. Immunology 84: 153-158, 1995.
159. R. Gabathuler, G. Reid, G. Kolaitis, J. Driscoll, and W.A. Jefferies. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med 180: 1415-1425, 1994.
160. M.P. Belich, R.J. Glynne, G. Senger, D. Sheer, and J. Trowsdale. Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins. Curr Biol 4: 769-776, 1994.
161. M. Kjerrulf, D. Grdic, L. Ekman, K. Schon, M. Vajdy, and N.Y. Lycke. Interferongamma receptor-deficient mice exhibit impaired gut mucosal immune responses but intact oral tolerance. Immunology 92: 60-68, 1997.
162. M. Nagao, Y. Nakajima, H. Kanehiro, M. Hisanaga, Y. Aomatsu, S. Ko, Y. Tatekawa, N. Ikeda, H. Kanokogi, Y. Urizono, T. Kobayashi, T. Shibaji, T. Kanamura, S. Ogawa, and H. Nakano. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology 32: 491-500, 2000.
163. I.M. Khouw, P.B. van Wachem, J.A. Plantinga, B.L. Haagmans, L.F. de Leij, and M.J. van Luyn. Foreign-body reaction to dermal sheep collagen in interferongamma- receptor knock-out mice. J Biomed Mater Res 50: 259-266, 2000.